tbuckley/cabot-search huggingface dataset:
ED-21 * INCIDENCE AND OUTCOMES IN BRAIN TUMORS OF JAPAN 2001-2004
Authors: Y. Narita, S. Shibui
Journal: Neuro-Oncology (2014)

BACKGROUND: The Brain Tumor Registry of Japan (BTRJ) was founded to investigate the statistical characteristics of brain tumors in Japan from 1975. The 13th edition of the BTRJ is published in 2014 (Neurologia medico-chirurgica Vol. 54 (2014) Supplement). METHODS: Data on primary or metastatic brain tumor cases that were newly diagnosed from 2001 to 2004 were collected from 2009 until the end of 2012. Approximately 330 neurosurgeons, medical doctors, and staff from 109 institutions collected 16,338 data from clinical records. These institutions included most universities, colleges, and hospitals with Japan Neurosurgical Society-authorized boards. These data were collected via the Internet Data and Information Center for Medical Research. Data, including the birthplace, age, tumor sites, diagnostic method, therapy (surgery, radiation, or chemotherapy), and the outcome of these treatments, according to the World Health Organization (WHO) 2007 brain tumor classification were collected. Survival data were analyzed using the Kaplan-Meier method. RESULTS: 5-year overall survival (OS) and 5-year progression free survival (PFS) of major brain tumors are as follows; grade II diffuse astrocytoma: 75%, 57%, grade II oligodendroglial tumor: 90%, 74.6%, grade III anaplastic astrocytoma: 41.1%, 28.7%, grade III anaplastic oligodendroglial tumor: 68.2%, 54%, glioblastoma: 10.1%, 9.2%, primary CNS lymphoma: 64.4%, 34.7%, null cell pituitary adenoma: 98.3%, 85.1%, neurinoma: 98.8%, 89.5%, grade I meningioma: 97.9%, 90.5%, grade II meningioma: 91.2%, 60.6%, grade III meningioma: 86.6%, 53.4%, chordoma: 89.1%,48.1%. CONCLUSIONS: Trends and problems in the treatment and outcomes of brain tumors of Japan in 2001-2004 will be presented and discussed.
SAT0382 Combination of quantitative ultrasound and frax® in evaluation of structural-functional state of bone in postmenopausal women
Authors: V. Povoroznyuk, N. Grygorieva, V. Povorozniuk
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> The aim of the study was to estimate the informative value of quantitative ultrasound and its combination with FRAX® in evaluation of structural-functional state of bone in Ukrainaian postmenopausal women. <h3>Objectives</h3> 363 postmenopausal women aged 45-87 years were examined, average age 65,1±0.5 years, duration of postmenopausal period 16,5±0.5 years. <h3>Methods</h3> Bone mineral density (BMD) was measured by Dual-energy X-ray absorptiometer (DXA) “Prodigy” and calcaneus quantitative ultrasound (QUS) “Sahara”. The ten years probability of major osteoporotic fracture calculated with FRAX® tool. <h3>Results</h3> There is difference in distribution of bone indexes in depending of used methods. Among women which had osteoporosis of femoral neck by DXA, 34% had osteoporosis, 57% - osteopenia, 9% - norma data by QUS. Sensitivity of QUS indexes ranging was from low to moderate, but specificity was low (with femoral neck – 38% and 39%, total hip – 63% and 34%, lumbar spine – 45% and 34%, total body – 56% and 34% accordingly). Such sensitivity and specificity increased when combining QUS with the ten years probability of major osteoporotic fracture without BMD (FRAX®) (with femoral neck – 71% and 87%, total hip – 90% and 100%, lumbar spine – 72% and 83%, total body – 79% and 91% accordingly). <h3>Conclusions</h3> QUS of is informative method in evaluation of structural-functional state of bone in postmenopausal women. Sensitivity and specificity increased when combining QUS with FRAX® from 38% and 34% up to 90% and 100% accordingly. <h3>Disclosure of Interest</h3> None Declared
Abstract 1344: ZAP-70 enhances migration of malignant B lymphocytes toward lymphoid organs in a Burkitt lymphoma xenograft model
Authors: Eva Calpe, Noelia Purroy, Pau Abrisqueta, Cecilia Carpio, Carles Palacio, Laura Gallur, Josep Castellvi, Marta Crespo, Francesc Bosch
Journal: Cancer Research (2012)

Abstract Chronic Lymphocytic Leukemia (CLL) is a lymphoproliferative disease characterized by the accumulation and proliferation of mature B-lymphocytes in the blood, bone marrow and secondary lymphoid organs. CLL patients with adverse outcome prognosis can be identified by the presence of a high ZAP-70 expression. ZAP-70, a protein tyrosine kinase that plays a crucial role in cellular activation in T and NK cells, has been related to aggressive features of the CLL cells, such as higher migrative capacity in vitro. In order to analyze the consequences of ZAP-70 ectopic expression in an in vivo model, we stably transfected a Burkitt cell line (Raji) with a vector expressing a ZAP-70-GFP fusion protein. Raji transfectants showed constitutively active ZAP-70 protein. Subsequently, thirty-four 8-week old SCID mice were inoculated intravenously with 5 x106 cells from each cell line (control Raji-GFP, 12 mice; Raji-ZAP-70-GFP, 9 mice). Mice were euthanized when hind legs paralysis, dyspnea, or tumor growth was observed. Organs were obtained to quantify the percentage of GFP-positive cells present in each organ by flow cytometry. Median survival of mice injected with the ZAP-70 cell line did not differ from that observed in the control mice (16 days, p=0.658). Percentage of GFP positive cells was analyzed by flow cytometry in different tissue compartments (Table 1). We observed a significantly higher percentage of infiltrating GFP-positive cells in the bone marrow from mice injected with ZAP-70 expressing cell line (58.8%±6.08 vs 4.2%±1.4, p&amp;lt;0.001), whereas in the rest of organs the infiltration was comparable (Table 1). Raji-ZAP-70-GFP has a differential expression of CCR7 and CD49d among others (Calpe et al, Blood 2011). In conclusion, malignant B-lymphocytes with ectopic expression of activated ZAP-70 protein showed enhanced ability to migrate toward and infiltrate the bone marrow, where soluble factors are produced to mediate homing, survival, and proliferation of tumor cells. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1344. doi:1538-7445.AM2012-1344
Stat Bite Pancreatic Cancer Incidence
Authors: B. Miller
Journal: JNCI Journal of the National Cancer Institute (1994)

Journal Article Stat Bite Pancreatic Cancer Incidence Get access Barry Miller Barry Miller Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 86, Issue 20, 19 October 1994, Pages 1497–1498, https://doi.org/10.1093/jnci/86.20.1497 Published: 19 October 1994
AI-11 * c-MET-MEDIATED ENDOTHELIAL-MESENCHYMAL TRANSITION DRIVES GLIOBLASTOMA PROGRESSION AND THERAPEUTIC RESISTANCE
Authors: M. Huang, P. Ma, R. Mitteer, Y. Fan
Journal: Neuro-Oncology (2014)

Excessive and abnormal vasculature characterizes the microenvironment that fuels the progression of malignant tumors including glioblastoma multiforme (GBM), the grade IV glioma. GBM is among the most lethal human malignancies, distinguished by extensive microvascular hyperplasia due to intravessel endothelial cell (EC) proliferation with unknown etiology. Here, we show that c-Met phosphorylation induces endothelial-mesenchymal transition (Endo-MT), contributing significantly to vascular abnormality, GBM progression, and therapeutic resistance. Utilizing murine orthotropic GBM models induced by transplantation of GL26 glioma cells and RCAS/tv-a-mediated somatic gene transfer of platelet-derived growth factor (PDGF) in Ink-4a/Arf−/-PTEN−/- mice, we reveal robust Endo-MT in tumor vasculature, characterized by expression of the fibroblast-specific marker FSP-1 in 60% of CD31+ or CD105+ ECs, and the co-expression level correlates with the aggressiveness of glioma in humans. Cell fate analysis by lineage tracing Tie2+ ECs shows over half of FSP-1+ fibroblasts are of EC origin in the mouse GBM models. Tumor-conditioned medium induces in vitro EC acquisition of mesenchymal gene signature including FSP-1 and N-cadherin expression, confirming the microenvironment-dependent Endo-MT. Furthermore, proteomic analysis identifies a critical role of c-Met in Endo-MT, which is required for the increased EC proliferation and migration and vessel hyperpermeability in the GBM microenvironment. EC-specific c-Met phosphorylation induces MMP-14 expression, leading to Endo-MT and vascular abnormality. Finally, pharmacological inhibition of c-Met phosphorylation normalizes blood vessels, reduces vascular density and Endo-MT, blocks tumor progression, and sensitizes tumor to temozolomide treatment; all of which improves overall survival in the GBM-bearing mice. These findings reveal a novel mechanism controlling aberrant vascularization and GBM progression, and suggest that targeting c-Met phosphorylation and Endo-MT may offer selective and efficient therapeutic strategies for the treatment-resistant GBM, and possibly other malignant tumors.
The suture-pulley method for endolumenal triangulation in endoscopic submucosal dissection
Authors: E. Rieder, K. Makris, D. Martinec, L. Swanström
Journal: Endoscopy (2011)

Endoscopic submucosal dissection (ESD) is a time-consuming and technically demanding technique [1] [2] [3]. The main difficulty is the lack of triangulated countertraction with current endoscopes [4]. To improve speed and efficacy of the procedure, an intriguing pulley method using dental floss together with endoscopic clips has recently been described [5]. However, current clip technology is unlikely to provide a robust and dependable anchor for this “pulley” technique.
Dyrk1a regulates the cardiomyocyte cell cycle via D-cyclin-dependent Rb/E2f-signalling
Authors: Susanne Hille, Franziska Dierck, Constantin Kühl, Justyna Sosna, Sabine Adam-Klages, Dieter Adam, Renate Lüllmann-Rauch, Norbert Frey, Christian Kuhn
Journal: Cardiovascular Research (2016)

Down syndrome-associated dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 1A (DYRK1A) is a ubiquitously expressed protein kinase. Up to date a variety of targets have been identified, establishing a key role for Dyrk1a in selected signalling pathways. In cardiomyocytes, Dyrk1a acts as a negative regulator of hypertrophy by phosphorylating transcription factors of the NFAT family, but its mechanistic function in the heart remains poorly understood. This study was designed to investigate a potential protective role of Dyrk1a in cardiac hypertrophy in vivo.We generated transgenic mice with cardiac-specific overexpression of Dyrk1a. Counterintuitively, these mice developed severe dilated cardiomyopathy associated with congestive heart failure and premature death. In search for the cause of this unexpected phenotype, we found that Dyrk1a interacts with all members of the D-cyclin family and represses their protein levels in vitro and in vivo. Particularly, forced expression of Dyrk1a leads to increased phosphorylation of Ccnd2 on Thr280 and promotes its subsequent proteasomal degradation. Accordingly, cardiomyocytes overexpressing Dyrk1a display hypo-phosphorylated Rb1, suppression of Rb/E2f-signalling, and reduced expression of E2f-target genes, which ultimately results in impaired cell cycle progression.We identified Dyrk1a as a novel negative regulator of D-cyclin-mediated Rb/E2f-signalling. As dysregulation of this pathway with impaired cardiomyocyte proliferation leads to cardiomyopathy, dose-specific Dyrk1a expression and activity appears to be critical for the hyperplastic and hypertrophic growth of the developing heart.
TCT-256 Benefit of Statin Pretreatment in Prevention of Contrast Induced Nephropathy: Systematic Review and Meta-analysis
Authors: Nirmal Singh, Justin Z. Lee, Anil Pandit, Jennifer J. Huang, See Wei Low, Prakash Suryanarayana, Tom Lassar, Kwan S. Lee
Journal: Journal of the American College of Cardiology (2014)
SECUNDUM ATRIAL SEPTAL DEFECT IS ASSOCIATED WITH REDUCED SURVIVAL IN ADULT MEN
Authors: Joey Mike Kuijpers, Teun van der Bom, Annelieke van Riel, Folkert Meijboom, Arie Van Dijk, Petronella Pieper, Hubert Vliegen, Marc Waskowsky, Toon Oomen, Carla Zomer, Wilfred Heesen, Lodewijk Wagenaar, Barbara Mulder, Jolien Roos-Hesselink, Berto Bouma, Aeilko Zwinderman
Journal: Journal of the American College of Cardiology (2015)
PRÓTESIS DE ESÓFAGO EN LA ESTENOSIS MALIGNA. ESTUDIO RETROSPECTIVO MULTICÉNTRICO
Authors: I De Lemos Simoes, V Lorenzo Zúñiga, MA Alvarez, A Seoane, V Moreno, JM Dedeu, L Barranco, J Boix, F Bory
Journal: Endoscopy (2010)

Introducción: La incidencia del cáncer de esófago está aumentando en los últimos años. La mayoría de los casos tienen una enfermedad no resecable cuando se diagnostican y la supervivencia general a los 5 años es desoladora (&lt;20%). La colocación de una prótesis esofágica autoexpandible (PEA), asociada o no a quimioterapia o radioterapia, es la practica clínica habitual para solucionar la disfagia maligna. Existen múltiples tipos de prótesis y no hay un consenso en su uso. Existe escasa información sobre la durabilidad de las prótesis y sus complicaciones tardías.
A STAGED DECOMPRESSION OF RIGHT VENTRICLE ALLOWS REGRESSION OF RIGHT VENTRICLE TO CORONARY ARTERY FISTULA AND SUBSEQUENT ACHIEVEMENT OF BIVENTRICULAR REPAIR IN PATIENTS WITH PULMONARY ATRESIA AND INTACT VENTRICULAR SEPTUM
Authors: Takahiro Eitoku, Yasuhiro Kotani, Kenji Baba, Maiko Kondou, Shingo Kasahara, Sadahiko Arai, Shinichi Ohtsuki, Shunji Sano
Journal: Journal of the American College of Cardiology (2016)
AB0818 Bone Mineral Density and Metabolic Risk Factors in Patients with Non-Erosive and Erosive Hand Osteoarthritis
Authors: O. Ruzickova, O. Sleglova, L. Senolt, K. Pavelka
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Hand osteoarthritis (OA) and its severe subset erosive hand OA are common causes of pain and morbidity in western world. Few studies investigated differences in systemic bone loss and metabolic diseases between non-erosive and erosive hand OA. <h3>Objectives</h3> To compare bone mineral density and metabolic risk factors between patients with erosive and non-erosive hand OA in a cross-sectional study. <h3>Methods</h3> Patients with symptomatic disease fulfilling the American College of Rheumatology (ACR) criteria for hand OA were included in this study. Erosive hand OA was defined by at least one erosive interphalangeal joint. All patients underwent clinical assessments of joint swelling and radiographs of both hands. DEXA examination of lumbar spine, total femur and femur neck was performed. Metabolic risk factors (body mass index, hypertension, diabetes, dyslipidaemia) and smoking habits were collected. <h3>Results</h3> 103 patients (nine male) with symptomatic nodal hand OA were included in this study between April 2012 and December 2013. Mean (SD) age of all patients was 66.1 (8.45) years and disease duration was 5.34 (7.63) years. Out of these patients, 56 had erosive hand OA. Baseline characteristics did not differ between both groups. In general, bone mineral density of lumbar (1.04 vs. 1.10 g/cm<sup>2</sup>) and total femur (0.91 vs. 0.95 g/cm<sup>2</sup>) was numerically, but not statistically significantly, lower in the group of erosive compared with non-erosive disease. Out of cardiovascular risk factors, there were more patients with dyslipidaemia (p&lt;0.01) and more cigarette smokers (p&lt;0.05) among patients with erosive compared with non-erosive hand OA. <h3>Conclusions</h3> Although these results do not support systemic bone loss in patients with erosive disease; it can be suggested that some metabolic factors and smoking may be implicated in the process of erosive hand OA. <h3>Acknowledgements</h3> This work was supported by the project MHCR No. 023728. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4497
Serious Neurologic Events after Epidural Glucocorticoid Injection — The FDA's Risk Assessment
Authors: Judith A. Racoosin, Sally M. Seymour, Laurelle Cascio, Rajdeep Gill
Journal: New England Journal of Medicine (2015)

Since 2014, injectable glucocorticoid product labels in the United States must carry a warning regarding the risk of serious neurologic events. After weighing the evidence and feedback from an advisory committee, the FDA has decided not to modify that warning.
SAT0217 Diagnostic value of labial minor salivary gland biopsy for primary sjögren’s syndrome: A systematic review:
Authors: D. Guellec, J.-O. Pers, A. Saraux, D. Cornec, T. Marhadour, P. Marcorelles, I. Quintin-Roué, S. Jousse-Joulin, V. Devauchelle-Pensec
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> The minor salivary gland biopsy (MSGB) plays a preponderant role in the American European Consensus Group (AECG) criteria set for primary and secondary Sjögren's syndrome (SS).However, its diagnostic value remains partially unclear and some authors have pointed out the lack of reproducibility of the results, and the lack of specificity of the test. <h3>Objectives</h3> To estimate the diagnostic value of MSGB for primary-SS, we performed a systematic review of published studies on MSGB for investigating SS. <h3>Methods</h3> PUBMED and EMBASE databases were searched. The following association of MeSh terms was used: "SJOGREN'S SYNDROME" in conjunction with "SALIVARY GLANDS" AND "BIOPSY". All publications published between January 1966 and June 2011 were considered. Selected publications were screened for additional relevant studies. We selected studies that considered a Focus Score (FS) ≥1 (or equivalent) as cut-off for a positive biopsy and concerning patients addressed for suspected SS. Sensibility and specificity of MSGB were collected, or calculated when possible. <h3>Results</h3> From the 237 publications identified, 8 were finally included in the study (table 1). Among these 8 studies, sensitivity ranged from 63.5% to 93.7% and specificity from 61.2% to 100%. Specificity was &gt;89% in 6 studies (Table 1). The differentiation between SS and non-SS patients was made without the help of MSGB or through a clinical reevaluation in only 2 studies. In these studies, sensitivity was respectively 63.9% and 85.7%, specificity was 91.9% and 89.7%. These 2 studies concerned 73 and 120 patients, evaluated for sicca symptoms in the first case and suspicion of primary-SS in the second. The gold standard for diagnosis of primary-SS was a set of criteria that did not include the MSGB in the first case and a reassessment of each patient by three experienced rheumatologists in the second (but not blinded to the MSGB). <h3>Conclusions</h3> Few studies are available in the literature to estimate the diagnostic value of MSGB for primary-SS. Only 2 studies used a methodology that avoids circular reasoning. Our study shows the lack of knowledge about the diagnostic value of MSGB, but confirm the good diagnosis value. The specificity of the test seems to be high, but the data about sensitivity is more heterogeneous. <h3>Disclosure of Interest</h3> None Declared
PMO-067 A response to NCEPOD (national clinical enquiry into patient outcome and death 2010) report—practice in provision of parenteral nutrition (PN) in a regional referral centre: Abstract PMO-067 Table 1
Authors: N Hamid, A Rochford, L Soo, L Barret, N Grasso, R Ali, F Rahman, A Forbes
Journal: Gut (2012)

<h3>Introduction</h3> The externally peer-reviewed NCEPOD report into the provision of PN alarmingly identified suboptimal care in 81% of patients receiving PN. We audited the quality of care received by parentally fed patients at a specialist regional centre for intestinal failure and home parenteral nutrition. <h3>Methods</h3> Data were collected retrospectively for 100 inpatients seen between April and December 2011 on an NCEPOD modified audit tool; case notes were reviewed. Type I and II intestinal failure patients were included; home parenteral nutrition patients were excluded from the study. <h3>Results</h3> Mean number of days patients were fed on PN was 12.2 (NCEPOD 13.2) and the range was 1–276 days (NCEPOD 1-212). 10% of patients were fed for 3 days or less (NCEPOD 10%) and 93% were fed for 30 days or less (NCEPOD 61%). The top two specialities referring patients were Colorectal 27% and Oncology 18% as compared to 22% from general surgery and 20% started in ICU in NCEPOD report. 12% referrals were deemed inappropriate and not started PN (NCEPOD 15%). <h3>Conclusion</h3> Our hospital is a regional centre for intestinal failure and PN is prescribed exclusively through the nutrition support team (NST). Thus in comparison with the NCEPOD findings, the PN service at UCLH is of a high standard. Data collection were sufficient for direct comparison with most NCEPOD report parameters. The NST appeared to prevent inappropriate use of PN by not starting 12% of referred patients. Although a similar proportion of our patients (10%) were fed for 3 days or less as found in the NCEPOD report, half of these patients were commenced on TPN in ICU. We found much lower rates of PN-related metabolic and catheter-related complications compared with the NCEPOD report because of active NST monitoring and good quality nursing care. Retrospective data collection on IV fluid prescribing was not possible, but it was perceived that there was some inappropriate use of IV fluids. A comprehensive database is being developed to enable prospective data collection to evaluate and develop the service further. <h3>Competing interests</h3> None declared. <h3>Reference</h3> 1. <b>NCEPOD</b>. <i>A Mixed Bag: The 2010 Report of the National Confidential Enquiry into Parenteral Nutrition</i>. London: NCEPOD, 2010.
BIPHASIC TRUNCATED EXPONENTIAL WAVEFORM IS SUPERIOR COMPARED TO PULSED BIPHASIC WAVEFORM IN CARDIOVERTING ATRIAL FIBRILLATION AND ATRIAL FLUTTER: A RANDOMIZED CONTROLLED TRIAL
Authors: Anders Sjørslev Schmidt, Kasper Lauridsen, Kasper Adelborg, Leif F. Bach, Simon M. Jepsen, Nete Hornung, Charles D. Deakin, Hans Rickers, Bo Løfgren
Journal: Journal of the American College of Cardiology (2015)
USE OF CLOPIDOGREL VERSUS PRASUGREL IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: FACTORS INFLUENCING REAL-WORLD THERAPEUTIC DECISION-MAKING
Authors: Olga Salianski, Usman Baber, Samantha Sartori, Melissa Aquino, Jaya Chandrasekhar, Annapoorna Kini, Sunil Rao, William Weintraub, Sandra Weiss, Timothy Henry, Samir Kapadia, Kanhaiya Poddar, Anthony DeFranco, J. Muhlestein, Catalin Toma, Mark Effron, Stuart Keller, Brian Baker, Stuart Pocock, Roxana Mehran
Journal: Journal of the American College of Cardiology (2016)
The Painful Accessory Navicular Bone
Authors: SAURIN SHAH, DWIGHT M. ACHONG
Journal: Clinical Nuclear Medicine (1999)

The accessory navicular bone is one of several supernumerary ossicles in the foot. Although considered a normal anatomic and radiographic variant, it may be the source of pain. Even when symptomatic, radiographs may be nondiagnostic. Bone scintigraphy, however, shows focal increased uptake in the symptomatic accessory navicular bone, reflecting ongoing bony metabolism and remodeling. Surgical excision often is required when conservative therapy fails. Histopathologic analysis reveals changes consistent with repetitive trauma and stress fracture. The scintigraphic and radiographic findings in a case of bilateral symptomatic and asymptomatic accessory navicular bones are presented.